EYS 606

Drug Profile

EYS 606

Alternative Names: EYS-606

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Eyevensys
  • Class
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Uveitis

Most Recent Events

  • 20 Apr 2017 The UK Medicines and Healthcare products Regulatory Agency (MHRA) approves for advancement into the clinic of EYS 606 for Uveitis
  • 11 Apr 2017 Agence Nationale de Sécurité du Médicament (ANSM) approves clinical trial application for EYS 606 in Uveitis
  • 15 Sep 2016 Eyevensys plans a phase Ib trial for Uveitis in France and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top